151. A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis
- Author
-
Alberto Martinez, Michel L. Aubert, Mark Christopher Elliott, Emmanuel Somm, Audrey Toulotte, Verity A Cadd, René Rizzoli, Petra Susan Hüppi, Shlomo Melmed, Richard B. Jones, Philip M H Marks, Nicolas Bonnet, Elaine Harper, and Serge Ferrari
- Subjects
Growth Hormone-Releasing Hormone/chemistry/genetics ,Male ,Botulinum Toxins ,Vesicle-Associated Membrane Protein 2 ,Pituitary Gland/drug effects/metabolism/pathology ,Down-Regulation/drug effects ,Growth Hormone-Releasing Hormone ,Recombinant Fusion Proteins/chemistry/pharmacology ,Rats, Sprague-Dawley ,Cyclic AMP ,Cyclic AMP/metabolism ,Growth Plate ,Insulin-Like Growth Factor I ,Receptor ,ddc:616 ,Growth Hormone/blood/secretion ,ddc:618 ,Insulin-Like Growth Factor I/genetics/metabolism/secretion ,Vesicle-Associated Membrane Protein 2/chemistry ,VAMP2 ,General Medicine ,Organ Size ,Growth hormone–releasing hormone ,Growth Inhibitors/chemistry/pharmacology ,Endopeptidase ,Growth Inhibitors ,Liver ,Pituitary Gland ,Area Under Curve ,Research Article ,Liver/metabolism ,medicine.medical_specialty ,endocrine system ,Somatotropic cell ,Acromegaly/drug therapy ,Recombinant Fusion Proteins ,Down-Regulation ,Biology ,Synaptic vesicle ,Exocytosis ,Cell Line ,Internal medicine ,medicine ,Animals ,Secretion ,Organ Size/drug effects ,Body Weight/drug effects ,Dose-Response Relationship, Drug ,Body Weight ,Botulinum Toxins/chemistry/genetics ,Prolactin ,Protein Structure, Tertiary ,Rats ,Endocrinology ,Growth Plate/drug effects/growth & development/pathology ,Prolactin/metabolism ,Growth Hormone ,Acromegaly ,ddc:618.97 ,Proteolysis - Abstract
Botulinum neurotoxins (BoNTs) are zinc endopeptidases that block release of the neurotransmitter acetylcholine in neuromuscular synapses through cleavage of soluble N-ethylmaleimide-sensitive fusion (NSF) attachment protein receptor (SNARE) proteins, which promote fusion of synaptic vesicles to the plasma membrane. We designed and tested a BoNT-derived targeted secretion inhibitor (TSI) targeting pituitary somatotroph cells to suppress growth hormone (GH) secretion and treat acromegaly. This recombinant protein, called SXN101742, contains a modified GH-releasing hormone (GHRH) domain and the endopeptidase domain of botulinum toxin serotype D (GHRH-LHN/D, where HN/D indicates endopeptidase and translocation domain type D). In vitro, SXN101742 targeted the GHRH receptor and depleted a SNARE protein involved in GH exocytosis, vesicle-associated membrane protein 2 (VAMP2). In vivo, administering SXN101742 to growing rats produced a dose-dependent inhibition of GH synthesis, storage, and secretion. Consequently, hepatic IGF1 production and resultant circulating IGF1 levels were reduced. Accordingly, body weight, body length, organ weight, and bone mass acquisition were all decreased, reflecting the biological impact of SXN101742 on the GH/IGF1 axis. An inactivating 2-amino acid substitution within the zinc coordination site of the endopeptidase domain completely abolished SXN101742 inhibitory actions on GH and IGF1. Thus, genetically reengineered BoNTs can be targeted to nonneural cells to selectively inhibit hormone secretion, representing a new approach to treating hormonal excess.
- Published
- 2012